LUNGS AND SYSTEMIC LUPUS ERYTHEMATO: A CLINICAL CASE OF THE EFFECTIVE USE OF NINTEDANIB IN THE TREATMENT OF COMMON INTERSTITIAL LUPUS PNEUMONIA

Rekalov D.G.¹, Danyuk I.O.²

• ¹National Scientific Center «Institute of Cardiology, Clinical and Regenerative Medicine named after Academician M.D. Strazheska National Academy of Sciences of Ukraine», Kyiv, Ukraine
• ²Zaporizhia State Medical and Pharmaceutical University, Zaporizhzhia, Ukraine

Summary. The article presents a clinical case of successful treatment of usual interstitial lupus-pneumonia with antifibrotic drug nintedanib. A 35-old female with a history of SLE and complains of dry cough and thorax pain during 3-months period. Computed tomography (CT) in the dynamics revealed the signs of usual interstitial pneumonia, which did not respond to treatment with glucocorticoids in medium doses. Based on complaints (chronic dry cough, chest pain), medical history (SLE since 2021), data of CT-scanning (stable signs of interstitial pneumonia during the 2-month of follow-up) interstitial lung disease (ILD) was suspected. Nintedanib at a dose of 200 mg/day orally was added to the patient’s treatment. After 4 months of treatment, repeated X-ray did not reveal focal or infiltrative changes, which indicates the high efficiency of this drug in the treatment of usual interstitial pneumonia and confirms that activation of fibrosis is the main link of pathogenesis of this type of ILD.